Vasopressin for Vasoplegic Shock Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Vasopressin for Vasoplegic Shock Market
The vasopressin for vasoplegic shock market size was valued at USD 890.9 million in 2019, and the market is now projected to grow USD 2657.9 million in 2027 exhibiting a CAGR of 14.8% during the forecast period of 2020-2027.
The vasopressin for vasoplegic shock market has been benefited by COVID-19 due to an increase in demand for the product owing to the rising cases. SARS is associated with increased prevalence of new or worsening cardiac disease, making vasopressin drugs important for infected patient. Therefore, there are more attentions on the supply and development of these treatments in the pharmaceutical industry. This demand spike has made the industry focus on the use of vasopressin in handling cardiac cases related to COVID-19.
There are more on-goings of cardiac surgeries, particularly CABG where vasopressin is used in managing blood flow not to result in sepsis. Currently 340000 CABG procedures are done annually in the United States of America and Vasoplegic Shock is a common complication. With these surgeries trending, there will be an uptake in demand for vasopressin for vasoplegic shock. This trend proves the importance of vasopressin in addressing some challenges that crop up with cardiac surgeries.
Vasoplegia develops in myocardial, septic, anaphylactic, and distributive shock; many pathways bear on the vascular substrate precise cardiac myocyte. Therefore, with increasing knowledge of these processes, approaches to the treatment of Sepsis are now becoming oriented to the individual twoand three-dimensional multiple therapies using various vasopressors. The constantly rising number of double-blind, randomized clinical trials assessing the efficacy of vasopressin in patients with critical illness and septic shock will also contribute to market growth. It is anticipated that this research will help to enhance and define the function of vasopressin in the treatment of vasoplegic shock.
Comprehensive Analysis of Vasopressin for Vasoplegic Shock Market
The vasopressin for vasoplegic shock market growth is rising at an exponential rate due to its market segmentation. This market expansion rightly provides a thorough market breakdown near to the industry considering the leading supply and demand forces. These segmentations are methodically segregated by application analysis. By application analysis includes sepsis, post-cardiac surgery, and others.
The North America region lead the vasopressin for vasoplegic shock market share by benefitting a market size of USD 561.3 million in 2019 due to increasing prevalence of sepsis across the region.
The top players in the markets have a central responsibility in the healthcare industry to be sure of industrial prospectus development and to establish the market norms. These players include, Endo International plc, AMOMED Pharma, La Jolla Pharmaceutical Company, Pfizer Inc., Ferring Pharmaceuticals, Fresenius Kabi Canada, Astellas Pharma, Eagle Pharmaceuticals, Inc. these market players provide a level-playing competitive landscape.
In April 2020, AMOMED Pharma announced the development of arginine vasopressin injection for treating septic shock in COVID-19 infected patients.
Segmentation Table
ATTRIBUTES DETAILS
Study Period 2016-2027
Base Year 2019
Forecast Period 2020-2027
Historical Period 2016-2018
Unit Value (USD Million)
Segmentation
By Application
Sepsis
Post Cardiac Surgery
Others
By Geography
North America (By Application and By Country)
The U.S. (By Application)
Canada (By Application)
Europe (By Application and By Country)
Germany (By Application)
UK (By Application)
France (By Application)
Italy (By Application)
Spain (By Application)
Scandinavia (By Application)
Rest of Europe (By Application)
Asia Pacific (By Application and By Country)
China (By Application)
India (By Application)
Japan (By Application)
Australia (By Application)
Southeast Asia (By Application)
Rest of Asia Pacific (By Application)
Latin America (By Application and By Country)
Brazil (By Application)
Mexico (By Application)
Rest of Latin America (By Application)
The Middle East & Africa (By Application and By Country)
South Africa (By Application)
Gcc Countries (By Application)
Rest of Middle East & Africa (By Application)Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Recent Industry Developments Such as Mergers & Acquisitions
- 4.2. Regulatory Scenario for Key Countries
- 4.3. New Product Launch
- 4.4. Statistics on Prevalence of Cardiac Disorders for Key Countries/Regions
- 4.5. Pipeline Analysis
- 5. Global Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Application
- 5.2.1. Sepsis
- 5.2.2. Post Cardiac Surgery
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast – By Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Latin America
- 5.3.5. Middle East & Africa
- 6. North America Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast - By Application
- 6.2.1. Sepsis
- 6.2.2. Post Cardiac Surgery
- 6.2.3. Others
- 6.3. Market Analysis, Insights and Forecast - By Country
- 6.3.1. U.S.
- 6.3.2. Canada
- 7. Europe Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast - By Application
- 7.2.1. Sepsis
- 7.2.2. Post Cardiac Surgery
- 7.2.3. Others
- 7.3. Market Analysis, Insights and Forecast - By Country/Sub Region
- 7.3.1. U.K.
- 7.3.2. Germany
- 7.3.3. France
- 7.3.4. Spain
- 7.3.5. Italy
- 7.3.6. Scandinavia
- 7.3.7. Rest of Europe
- 8. Asia Pacific Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast - By Application
- 8.2.1. Sepsis
- 8.2.2. Post Cardiac Surgery
- 8.2.3. Others
- 8.3. Market Analysis, Insights and Forecast - By Country/Sub Region
- 8.3.1. Japan
- 8.3.2. China
- 8.3.3. India
- 8.3.4. Australia
- 8.3.5. Southeast Asia
- 8.3.6. Rest of Asia Pacific
- 9. Latin America Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast - By Application
- 9.2.1. Sepsis
- 9.2.2. Post Cardiac Surgery
- 9.2.3. Others
- 9.3. Market Analysis, Insights and Forecast - By Country/Sub Region
- 9.3.1. Brazil
- 9.3.2. Mexico
- 9.3.3. Rest of Latin America
- 10. Middle East & Africa Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027
- 10.1. Key Findings / Summary
- 10.2. Market Analysis, Insights and Forecast - By Application
- 10.2.1. Sepsis
- 10.2.2. Post Cardiac Surgery
- 10.2.3. Others
- 10.3. Market Analysis, Insights and Forecast - By Country/Sub Region
- 10.3.1. GCC Countries
- 10.3.2. South Africa
- 10.3.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Key Industry Developments
- 11.2. Global Market Share Analysis (2019)
- 11.3. Competition Dashboard
- 11.4. Comparative Analysis – Major Players
- 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 11.5.1. Endo International plc
- 11.5.1.1. Overview
- 11.5.1.2. Products & services
- 11.5.1.3. SWOT analysis
- 11.5.1.4. Recent developments
- 11.5.1.5. strategies
- 11.5.1.6. financials (based on availability)
- 11.5.2. AMOMED Pharma
- 11.5.2.1. Overview
- 11.5.2.2. Products & services
- 11.5.2.3. SWOT analysis
- 11.5.2.4. Recent developments
- 11.5.2.5. strategies
- 11.5.2.6. financials (based on availability)
- 11.5.3. La Jolla Pharmaceutical Company
- 11.5.3.1. Overview
- 11.5.3.2. Products & services
- 11.5.3.3. SWOT analysis
- 11.5.3.4. Recent developments
- 11.5.3.5. strategies
- 11.5.3.6. financials (based on availability)
- 11.5.4. Pfizer Inc.
- 11.5.4.1. Overview
- 11.5.4.2. Products & services
- 11.5.4.3. SWOT analysis
- 11.5.4.4. Recent developments
- 11.5.4.5. strategies
- 11.5.4.6. financials (based on availability)
- 11.5.5. Ferring Pharmaceuticals
- 11.5.5.1. Overview
- 11.5.5.2. Products & services
- 11.5.5.3. SWOT analysis
- 11.5.5.4. Recent developments
- 11.5.5.5. strategies
- 11.5.5.6. financials (based on availability)
- 11.5.6. Fresenius Kabi Canada
- 11.5.6.1. Overview
- 11.5.6.2. Products & services
- 11.5.6.3. SWOT analysis
- 11.5.6.4. Recent developments
- 11.5.6.5. strategies
- 11.5.6.6. financials (based on availability)
- 11.5.7. Astellas Pharma
- 11.5.7.1. Overview
- 11.5.7.2. Products & services
- 11.5.7.3. SWOT analysis
- 11.5.7.4. Recent developments
- 11.5.7.5. strategies
- 11.5.7.6. financials (based on availability)
- 11.5.8. Eagle Pharmaceuticals, Inc.
- 11.5.8.1. Overview
- 11.5.8.2. Products & services
- 11.5.8.3. SWOT analysis
- 11.5.8.4. Recent developments
- 11.5.8.5. strategies
- 11.5.8.6. financials (based on availability)
- 11.5.9. Others
- 11.5.9.1. Overview
- 11.5.9.2. Products & services
- 11.5.9.3. SWOT analysis
- 11.5.9.4. Recent developments
- 11.5.9.5. strategies
- 11.5.9.6. financials (based on availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook